Autonomix Medical, Inc. filings document a development-stage medical device company focused on precision nerve-targeted technology and transvascular approaches to peripheral nerve sensing and treatment. Securities registration statements describe the company’s common stock, warrant instruments, offering mechanics, emerging growth company status, smaller reporting company status, financial statements, convertible note proceeds, and related-party transaction disclosures.
Autonomix’s 8-K filings cover material events including Regulation FD clinical-data disclosures, private placement financing agreements involving pre-funded warrants and Series C warrants, annual meeting voting results, board and auditor matters, reverse stock split authority, and Nasdaq continued-listing compliance notices. These records also reflect capital-structure changes and governance actions tied to the company’s public-company status.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Smith Trent N. reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that its chief financial officer, Trent N. Smith, received a grant of 15,000 shares of common stock on September 3, 2026 as a restricted stock award that vests one year from that date. Following this equity award, he directly holds 15,119 shares of Autonomix Medical common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Autonomix Medical, Inc. (AMIX) is registering up to 1,071,826 shares of common stock for resale by a single selling stockholder, all issuable upon exercise of outstanding Series E warrants with a $6.25 exercise price. Autonomix will not receive proceeds from resale, only from any cash exercises of the warrants.
If all warrants are exercised for cash, Autonomix would receive up to $6.7 million, which it plans to use for working capital, though the company notes the warrants may never be exercised or may be exercised on a cashless basis. As of August 31, 2026, 1,828,505 shares of common stock were outstanding, so the registered warrant shares represent a large potential increase in tradable stock.
The company recently completed a 1-for-21 reverse stock split on June 24, 2026, reducing outstanding shares from 11,409,344 to 542,312, and its auditor has included an explanatory paragraph expressing substantial doubt about Autonomix’s ability to continue as a going concern. The prospectus highlights that resale of a large block of shares and warrant exercises could materially dilute existing stockholders and pressure the trading price.
Autonomix Medical, Inc. (AMIX) reported that its Board of Directors increased its size from five to six members and appointed Sandra Cohen Kalter
Kalter brings more than four decades of MedTech, FDA regulatory and strategic transaction experience, including 20 years in senior legal and regulatory leadership roles at Medtronic plc, where she served as Vice President and Chief Regulatory Counsel. Her background also includes 13 years as FDA/Healthcare Counsel at King & Spalding LLP and prior board and committee service at key industry organizations.
Autonomix Medical, Inc. (AMIX) is asking stockholders at the October 29, 2026 annual meeting to re-elect six directors, ratify Forvis Mazars, LLP as auditor, approve Board discretion to implement a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-25 within one year, and approve an amended and restated 2023 Equity Incentive Plan that increases shares authorized for issuance. There were 1,959,938 shares of common stock outstanding as of September 8, 2026, each with one vote.
The company highlights prior reverse splits in October 2024 (1-for-20) and June 2026 (1-for-21), notes that authorized common shares will remain at 500,000,000, and discloses significant potential issuance capacity via options, warrants and plan shares. Governance disclosures describe a majority-independent board, three key board committees, anti-hedging and insider trading policies, and a Dodd-Frank compliant clawback policy. The proxy also details 2026 executive pay, bonuses tied to achieving corporate milestones, and new restricted stock awards granted in September 2026.
Autonomix Medical, Inc. (AMIX) has established an at-the-market equity program under which it may sell shares of common stock with an aggregate offering price of up to $10.525 million from time to time through Ladenburg Thalmann as sales agent or principal. Ladenburg will receive a 3.0% cash commission on gross proceeds and may also conduct privately negotiated transactions, with no minimum sale amount and no escrow arrangement. Based on a September 8, 2026 closing price of $4.58 and 1,959,938 shares outstanding, the company illustrates that issuing 2,298,035 shares would increase shares outstanding to 4,257,973, subject to the 500,000,000 authorized share limit and one‑third public float constraints under Form S‑3 Instruction I.B.6. Autonomix intends to use any net proceeds for working capital and general corporate purposes. The company is a development‑stage medical device business with no product sales revenue, an auditor’s going‑concern explanatory paragraph, and significant risks including potential Nasdaq delisting if a new $5 million Market Value of Listed Securities rule ultimately takes effect and is not satisfied, as well as dilution and price volatility from this ATM program.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. KLEMP WALTER V reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that director Walter V. Klemp received a grant of 13,000 shares of Common Stock as a restricted stock award on September 3, 2026. Following this equity award, he holds 20,118 shares directly, with the award vesting one year from September 3, 2026.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Bisson Lori reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that director Lori Bisson received a grant of 13,000 shares of common stock on September 3, 2026 as a restricted stock award, bringing her direct holdings to 13,119 shares.
The award is scheduled to vest one year from the issuance date, on September 3, 2027. No transactions are reported under a Rule 10b5-1 trading plan.
Autonomix Medical, Inc. (symbol: AMIX) is the issuer of record for a Form 4 filing submitted to the SEC. Hauser Bradley reported acquisition or exercise transactions in this Form 4 filing.
Autonomix Medical, Inc. (AMIX) reported that CEO and President Bradley Hauser received an equity grant of 27,000 shares of Common Stock on September 3, 2026. The award is described as a restricted stock award vesting one year from the date of issuance of September 3, 2026, and is held as direct ownership. No Rule 10b5-1 trading plan is reported for this grant.